Neovascular Age-related Macular Degeneration (nAMD) is a progressive fibrotic condition characterized by abnormal vasculature growth under the retina, leakage from which triggers a fibrotic immune response leading to irreversible damage and blindness. Early detection and accurate diagnosis of nAMD are citical for effective management, however current methods often fail to detect early stage disease and assess the full extent of fibrosis. Collagen Hybridizing Peptides have been shown to bind to fibrotic scarring in nAMD for the continuous monitoring of disease progression and response to treatment.
In collaboration with partners at Roche Ophthalmology, we have shown that Collagen Hybridizing Peptides bind to fibrotic scarring in nAMD previously defined only as Subretinal Highly Reflective Material (SHRM). This ability allowed our partners to monitor the efficacy of their subretinal fibrosis treatment.
Collagen Hybridizing Peptides are ideal for monitoring the progression of fibrosis in vivo. Furthermore, where longitudinal animal studies typically require animal sacrifice to show progression, it is not necessary with CHPs, improving data continuity and enabling real-time monitoring.
Linder, Markus, et al. "In vivo monitoring of active subretinal fibrosis in mice using collagen hybridizing peptides." Lab Animal (2024): 1-9.
Dabouz, Rabah, et al. "Mast cells promote choroidal neovascularization in a model of age-related macular degeneration." Journal of Neuroinflammation 21.1 (2024): 247.Corano Scheri, Katia, et al. "Limited Hyperoxia-Induced Proliferative Retinopathy (LHIPR) as a Model of Retinal Fibrosis, Angiogenesis, and Inflammation." Cells 12.20 (2023): 2468.
Thanks for subscribing!
This email has been registered!